The use of the FreeStyle Libre continuous glucose monitoring system is associated with significant reductions in HbA1c, new data from has revealed. CGM is widely recognised as standard of care technology for people living with type 1 diabetes, and there is a growing consensus in support of CGM use for people with type 2 diabetes. FreeStyle Libre 2 was previously covered only for people with type 1 and type 2 diabetes who require intensive insulin therapy. The expanded reimbursement follows similar reimbursement coverage expansions for its technology in Japan and the US, which together represents three million more people living with diabetes who are now eligible to use FreeStyle Libre technology to manage their condition. Neil Harris, general manager for Abbott’s diabetes care business in the UK and Ireland, said: “The compelling body of evidence demonstrates what we already know – that FreeStyle Libre technology is making a significant difference for people living with diabetes.

Source: The Times October 04, 2023 08:59 UTC